Science Explorer Back to mapMap

Most cited papers from Shafran Gastroenterology Center

What are the most cited papers from Shafran Gastroenterology Center?

The most cited paper from Shafran Gastroenterology Center is "North American Regional Reanalysis" (Fedor Mesinger, Geoff DiMego, Eugenia Kalnay et al., 2006), with 3,526 citations. Next come "Long-term Efficacy of Vedolizumab for Ulcerative Colitis" (222) and "Long-term Efficacy of Vedolizumab for Crohn’s Disease" (216).

Showing 48 of 48 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 North American Regional Reanalysis Fedor Mesinger, Geoff DiMego, Eugenia Kalnay et al. · Bulletin of the American Meteorological Society Open access Mar 2006 3,526
2 Long-term Efficacy of Vedolizumab for Ulcerative Colitis Edward V. Loftus, Jean‐Frédéric Colombel, Brian G. Feagan et al. · Journal of Crohn s and Colitis Open access 28 Sep 2016 222
3 Long-term Efficacy of Vedolizumab for Crohn’s Disease Severine A.R.A. Vermeire, Edward V. Loftus, Jean‐Frédéric Colombel et al. · Journal of Crohn s and Colitis Open access 28 Sep 2016 216
4 A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease Robert B. Burakoff, Charles F. Barish, Dennis Riff et al. · Inflammatory Bowel Diseases 27 Jun 2006 111
5 Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis Mark T. Osterman, Faten N. Aberra, Raymond Keith Cross et al. · Clinical Gastroenterology and Hepatology Open access 30 Apr 2014 93
6 An open-label evaluation of rifaximin in the treatment of active Crohn's disease Ira Shafran, Lorin K. Johnson · Current Medical Research and Opinion 24 Jun 2005 68
7 Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study Claudia Peña Rossi, Stephen B. Hanauer, Ratko Tomašević et al. · BMC Gastroenterology Open access 20 Mar 2009 49
8 Utility of video capsule endoscopy for longitudinal monitoring of Crohn’s disease activity in the small bowel: a prospective study GIL Y. MELMED, Marla C. Dubinsky, David T. Rubin et al. · Gastrointestinal Endoscopy Open access 4 Aug 2018 46
9 Adjunctive Antibiotic Therapy with Rifaximin May Help Reduce Crohn’s Disease Activity Ira Shafran, Patricia Burgunder · Digestive Diseases and Sciences 28 Jan 2010 43
10 Presence of Infection by Mycobacterium avium subsp. paratuberculosis in the Blood of Patients with Crohn’s Disease and Control Subjects Shown by Multiple Laboratory Culture and Antibody Methods J. Todd Kuenstner, Raghava Potula, Tim John Bull et al. · Microorganisms Open access 21 Dec 2020 26
11 Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin Ira Shafran, Patricia Burgunder, David Wei et al. · Therapeutic Advances in Gastroenterology Open access 9 Jul 2015 26
12 Rifaximin for the Treatment of Newly Diagnosed Crohn's Disease: A Case Series Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Aug 2008 16
13 Efficacy and tolerability of rifaximin, a nonabsorbed oral antibiotic, in the treatment of active Crohn?s disease: results of an open-label study Ira Shafran · The American Journal of Gastroenterology Sep 2003 12
14 Visual Field Outcome Reporting in Neurosurgery: Lessons Learned from a Prospective, Multicenter Study of Transsphenoidal Pituitary Surgery Michael A. Mooney, Angela M. Herro, Robert E. Fintelmann et al. · World Neurosurgery 22 Aug 2018 7
15 Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned Anita Afzali, Matthew A. Ciorba, David A. Schwartz et al. · Inflammatory Bowel Diseases 19 Dec 2017 5
16 Evaluation of mucosal healing in Small Bowel Crohn’s disease treated with Certolizumab Pegol assessed by wireless capsule endoscopy Ira Shafran, Patricia Burgunder, Renee DePanicis et al. · Clinical Case Reports and Reviews Open access 2016 3
17 Mobile and Web-Based Application for IBD Tracking Ira Shafran, Patricia Burgunder, B Shamosh · Inflammatory Bowel Diseases Open access Dec 2009 3
18 P-006 Evidence of Mucosal Healing in Patients with Crohnʼs Disease Treated with Open-Label Vedolizumab Ira Shafran, R Laughlin, Patricia Burgunder · Inflammatory Bowel Diseases 5 Feb 2016 2
19 Potential pathogenic role of Mycobacterium avium subspecies paratuberculosis in Crohnʼs disease Ira Shafran, Patricia Burgunder · Inflammatory Bowel Diseases 28 May 2008 2
20 Oral Serum-derived Bovine Immunoglobulin/Protein Isolate (SBI) in a Large, Single Center Experience Improves Symptomatology in Patients With Inflammatory Bowel Disease and Irritable Bowel Syndrome Ira Shafran, Patricia Burgunder, Andrew Bertot · The American Journal of Gastroenterology Oct 2014 1
21 Long-Term Safety and Efficacy of Certolizumab Pegol Therapy in Patients With Moderate to Severe Crohnʼs Disease: 5-Year Results Theadore Ptak, Ziad H Younes, Ira Shafran et al. · The American Journal of Gastroenterology Oct 2015 1
22 Efficacy of Adalimumab Therapy in Patients with Crohnʼs Disease Who Were Unresponsive to or Intolerant of Infliximab: Six Years of Experience in a Single Gastroenterology Center Ira Shafran, David J. Cangemi, Patricia Burgunder · The American Journal of Gastroenterology Oct 2010 1
23 Efficacy of adalimumab therapy in patients with Crohn's disease who were unresponsive to or intolerant of infliximab Ira Shafran, David J. Cangemi, Patricia Burgunder · Inflammatory Bowel Diseases 2011 1
24 The Use of Wireless Capsule Endoscopy in Community Practice: An 11 Year Experience Ira Shafran, Patricia Burgunder, Michael C. Kwa · Inflammatory Bowel Diseases Dec 2012 1
25 Is monotherapy with an oral antibiotic useful in reducing Crohnʼs disease activity? Ira Shafran · Inflammatory Bowel Diseases May 2007 0
26 Comparative analysis of IBD serology Patricia Burgunder, Ira Shafran, T Aplin · Inflammatory Bowel Diseases Dec 2008 0
27 Retrospective Chart Review Study of Patients Receiving Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) for Nutritional Management of Irritable Bowel Syndrome with Diarrhea (IBS-D) Larry I. Good, Leonard B. Weinstock, Ira Shafran et al. · The American Journal of Gastroenterology Oct 2016 0
28 Rifaximin Monotherapy Was Effective in Patients with Newly Diagnosed Crohnʼs Disease Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Sep 2008 0
29 Rifaximin Maintenance Therapy for Crohnʼs Disease Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Oct 2009 0
30 Clinical Management of Lymphocytic Colitis With Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) Christine L. Frissora, Ira Shafran, Steven H. Silver et al. · The American Journal of Gastroenterology Oct 2015 0
31 Open Label Investigation of Mucosal Healing in Patients with Small Bowel Crohnʼs Disease Treated with Certolizumab Pegol Assessed by Wireless Capsule Endoscopy Ira Shafran, Patricia Burgunder, Alexander Max Fagenson · The American Journal of Gastroenterology Oct 2011 0
32 Evaluation of Serology Results from Patients with Inflammatory Bowel Disease Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Oct 2009 0
33 Gender Differences in Infliximab Durability: A Single Center 13 Year Experience Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Oct 2011 0
34 A Single Centerʼs Experience with Capsule Endoscopy in 74 Patients with Crohnʼs Disease: Is It Safe? Ira Shafran, Patricia Burgunder, Michael C. Kwa · The American Journal of Gastroenterology Oct 2011 0
35 Comparison of Computed Tomographic Enterography with Standard Diagnostic Assessments for Detecting Active Crohnʼs Disease Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Sep 2008 0
36 Monitoring Patients with Ulcerative Colitis in Community-Based Practice to Improve Adherence Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Sep 2008 0
37 Monitoring Adherence and Outcomes in Patients with Inflammatory Bowel Disease Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Oct 2009 0
38 Efficacy of Certolizumab Pegol Therapy in Patients With Crohnʼs Disease Ira Shafran, Sayel Al-Maani, Patricia Burgunder · The American Journal of Gastroenterology Oct 2010 0
39 Health Maintenance Strategies for the IBD Patient in Private Practice Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Oct 2010 0
40 Mesalamine Granules for the Treatment of Crohnʼs Colitis: A Case Study Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Oct 2010 0
41 Assessment of the Validity of Computed Tomographic Enterography for Diagnosing Active Crohnʼs Disease Patricia Burgunder, Ira Shafran · The American Journal of Gastroenterology Sep 2007 0
42 Rifaximin for the Treatment of Newly Diagnosed Crohnʼs Disease Ira Shafran, Patricia Burgunder · The American Journal of Gastroenterology Sep 2007 0
43 Economic and Clinical Impact of Serum-Derived Bovine Immunoglobulin / Protein Isolate (SBI) in the Management of Chronic Diarrhea in Inflammatory Bowel Disease (IBD) Cortni Tyson, Ira Shafran, Raouf E. Hilal et al. · Value in Health Open access Oct 2017 0
44 Certolizumab pegol as treatment for Crohnʼs disease in a community IBD practice Ira Shafran, Patricia Burgunder, Faisal Fakih · Inflammatory Bowel Diseases Dec 2011 0
45 Newly diagnosed Crohnʼs cisease: case series of rifaximin monotherapy Ira Shafran, Patricia Burgunder · Inflammatory Bowel Diseases 2008 0
46 Long-term Rifaximin Treatment for Newly Diagnosed Crohnʼs Disease Ira Shafran, Patricia Burgunder · Inflammatory Bowel Diseases Open access Dec 2009 0
47 Adalimumab Therapy for Patients With Crohnʼs Disease Who Are Unresponsive to or Intolerant of Infliximab Ira Shafran, Patricia Burgunder, A Fakih · Inflammatory Bowel Diseases Dec 2009 0
48 Does Combination Therapy using Rifaximin with Adalimumab improve Crohnʼs Disease activity and Mucosal Healing? A Case Series Ira Shafran, Patricia Burgunder · Inflammatory Bowel Diseases Dec 2009 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.